Pacira BioSciences, Inc. (PCRX)
USD 24.97
(1.67%)
USD 24.97
(1.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 490.3 Million USD | -7.38% |
| 2022 | 467.52 Million USD | 16.51% |
| 2021 | 401.27 Million USD | 32.22% |
| 2020 | 303.5 Million USD | -3.44% |
| 2019 | 314.31 Million USD | 25.51% |
| 2018 | 250.43 Million USD | 26.03% |
| 2017 | 198.71 Million USD | 19.52% |
| 2016 | 166.26 Million USD | -6.15% |
| 2015 | 177.16 Million USD | 47.35% |
| 2014 | 120.22 Million USD | 290.62% |
| 2013 | 30.77 Million USD | 343.18% |
| 2012 | 6.94 Million USD | 761.43% |
| 2011 | -1.05 Million USD | -145.93% |
| 2010 | 2.28 Million USD | -15.49% |
| 2009 | 2.7 Million USD | 176.46% |
| 2008 | -3.53 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 119.43 Million USD | 13.34% |
| 2024 Q1 | 105.37 Million USD | -11.62% |
| 2023 Q3 | 124.17 Million USD | 2.4% |
| 2023 Q4 | 119.23 Million USD | -3.98% |
| 2023 FY | 433.02 Million USD | -7.38% |
| 2023 Q2 | 121.26 Million USD | 8.93% |
| 2023 Q1 | 111.32 Million USD | 1.17% |
| 2022 Q4 | 110.03 Million USD | -5.78% |
| 2022 Q2 | 118.78 Million USD | -2.57% |
| 2022 Q1 | 121.91 Million USD | 1.44% |
| 2022 FY | 467.52 Million USD | 16.51% |
| 2022 Q3 | 116.78 Million USD | -1.68% |
| 2021 Q2 | 100.34 Million USD | 14.44% |
| 2021 Q1 | 87.67 Million USD | -5.98% |
| 2021 Q4 | 120.18 Million USD | 29.13% |
| 2021 Q3 | 93.07 Million USD | -7.25% |
| 2021 FY | 401.27 Million USD | 32.22% |
| 2020 Q1 | 75.95 Million USD | -16.09% |
| 2020 FY | 303.5 Million USD | -3.44% |
| 2020 Q2 | 53.2 Million USD | -29.96% |
| 2020 Q3 | 87.49 Million USD | 64.46% |
| 2020 Q4 | 93.25 Million USD | 6.58% |
| 2019 Q4 | 90.52 Million USD | 9.88% |
| 2019 Q2 | 77.4 Million USD | 20.92% |
| 2019 Q3 | 82.38 Million USD | 6.43% |
| 2019 FY | 314.31 Million USD | 25.51% |
| 2019 Q1 | 64.01 Million USD | -10.02% |
| 2018 Q3 | 64.38 Million USD | 1.89% |
| 2018 Q1 | 51.72 Million USD | -10.49% |
| 2018 FY | 250.43 Million USD | 26.03% |
| 2018 Q4 | 71.13 Million USD | 10.49% |
| 2018 Q2 | 63.19 Million USD | 22.17% |
| 2017 FY | 198.71 Million USD | 19.52% |
| 2017 Q4 | 57.78 Million USD | 17.67% |
| 2017 Q3 | 49.1 Million USD | 4.21% |
| 2017 Q2 | 47.12 Million USD | 5.42% |
| 2017 Q1 | 44.7 Million USD | -9.29% |
| 2016 Q4 | 49.28 Million USD | 95.54% |
| 2016 Q2 | 46.58 Million USD | 3.08% |
| 2016 Q1 | 45.19 Million USD | -9.41% |
| 2016 FY | 166.26 Million USD | -6.15% |
| 2016 Q3 | 25.2 Million USD | -45.9% |
| 2015 Q1 | 40.73 Million USD | -4.88% |
| 2015 Q4 | 49.89 Million USD | 7.73% |
| 2015 FY | 177.16 Million USD | 47.35% |
| 2015 Q3 | 46.31 Million USD | 15.15% |
| 2015 Q2 | 40.21 Million USD | -1.27% |
| 2014 Q4 | 42.82 Million USD | 35.28% |
| 2014 FY | 120.22 Million USD | 290.62% |
| 2014 Q3 | 31.65 Million USD | 16.34% |
| 2014 Q2 | 27.21 Million USD | 46.81% |
| 2014 Q1 | 18.53 Million USD | 22.03% |
| 2013 Q4 | 15.18 Million USD | 79.37% |
| 2013 Q1 | 196 Thousand USD | -74.81% |
| 2013 FY | 30.77 Million USD | 343.18% |
| 2013 Q2 | 6.92 Million USD | 3434.18% |
| 2013 Q3 | 8.46 Million USD | 22.25% |
| 2012 Q2 | 5.65 Million USD | 332.31% |
| 2012 Q1 | 1.3 Million USD | 155.28% |
| 2012 Q3 | -801 Thousand USD | -114.15% |
| 2012 Q4 | 778 Thousand USD | 197.13% |
| 2012 FY | 6.94 Million USD | 761.43% |
| 2011 FY | -1.05 Million USD | -145.93% |
| 2011 Q1 | 196 Thousand USD | 136.14% |
| 2011 Q2 | 521 Thousand USD | 165.82% |
| 2011 Q3 | 599 Thousand USD | 14.97% |
| 2011 Q4 | -2.36 Million USD | -495.33% |
| 2010 Q4 | 83 Thousand USD | -91.35% |
| 2010 Q3 | 959 Thousand USD | 365.53% |
| 2010 Q2 | 206 Thousand USD | -80.15% |
| 2010 Q1 | 1.03 Million USD | 28.78% |
| 2010 FY | 2.28 Million USD | -15.49% |
| 2009 Q3 | 1.04 Million USD | 0.0% |
| 2009 Q4 | 806 Thousand USD | -22.57% |
| 2009 FY | 2.7 Million USD | 176.46% |
| 2008 FY | -3.53 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -50.324% |
| Embecta Corp. | 749.9 Million USD | 34.617% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -60.598% |
| Dynavax Technologies Corporation | 182.11 Million USD | -169.227% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -571.04% |
| PainReform Ltd. | -15 Thousand USD | 3268826.667% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -1547.987% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5779.589% |
| SCYNEXIS, Inc. | 124.51 Million USD | -293.769% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -88408.063% |
| Cosmos Health Inc. | 4.34 Million USD | -11172.588% |
| Journey Medical Corporation | 52.52 Million USD | -833.548% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5779.589% |
| Safety Shot Inc | -74.45 Thousand USD | 658612.967% |
| Alpha Teknova, Inc. | 10.29 Million USD | -4662.131% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | -13.86% |
| Bright Green Corporation | -237.01 Thousand USD | 206967.469% |
| Procaps Group, S.A. | 239.56 Million USD | -104.663% |
| Theratechnologies Inc. | 62.12 Million USD | -689.179% |
| Harrow Health, Inc. | 90.55 Million USD | -441.461% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -10233.172% |
| Biofrontera Inc. | 16.62 Million USD | -2848.872% |
| DURECT Corporation | 6.83 Million USD | -7077.705% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 6.383% |
| Cronos Group Inc. | 6.99 Million USD | -6913.536% |
| OptiNose, Inc. | 62.35 Million USD | -686.331% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | -11.141% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 161918.152% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -15953.74% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -58.271% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -8989.025% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -1364.225% |
| Radius Health, Inc. | 307.71 Million USD | -59.341% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -4765.2% |
| ProPhase Labs, Inc. | 16.23 Million USD | -2919.33% |
| Phibro Animal Health Corporation | 312.48 Million USD | -56.905% |
| Procaps Group S.A. | 239.56 Million USD | -104.663% |
| Alvotech | -69.42 Million USD | 806.273% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -37558.141% |
| Viatris Inc. | 6.43 Billion USD | 92.385% |
| Rockwell Medical, Inc. | 8.7 Million USD | -5533.146% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -798.232% |
| SIGA Technologies, Inc. | 122.09 Million USD | -301.589% |
| Tilray Brands, Inc. | 223.35 Million USD | -119.524% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -1071.587% |
| Shineco, Inc. | 882.16 Thousand USD | -55480.003% |
| PetIQ, Inc. | 252.74 Million USD | -93.997% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 65861.386% |
| Incannex Healthcare Limited | 12 Thousand USD | -4085808.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 73.46% |
| Alimera Sciences, Inc. | 61.17 Million USD | -701.551% |
| Silver Spike Investment Corp. | 8.1 Million USD | -5951.256% |
| Assertio Holdings, Inc. | 125.04 Million USD | -292.093% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 7198881.383% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -11598.624% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -7378.783% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 20443.286% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1708.124% |
| Hempacco Co., Inc. | -1.21 Million USD | 40427.002% |
| Talphera, Inc. | -4.89 Million USD | 10116.527% |
| Alvotech | -69.42 Million USD | 806.273% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | -121.185% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 30.898% |
| Currenc Group, Inc. | 17.35 Million USD | -2724.962% |
| Kamada Ltd. | 52.59 Million USD | -832.275% |
| Indivior PLC | 907 Million USD | 45.942% |
| Evoke Pharma, Inc. | 4.97 Million USD | -9748.032% |
| Flora Growth Corp. | 17.73 Million USD | -2664.173% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 20443.286% |
| Evolus, Inc. | 140.52 Million USD | -248.91% |
| HUTCHMED (China) Limited | 453.55 Million USD | -8.104% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | -42.545% |
| Akanda Corp. | 111.44 Thousand USD | -439840.242% |